Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

Background As the COVID-19 pandemic continues to spread, the number of associated
deaths continues to increase, especially among those with pre-existing conditions. Azvudine …

Background: The sixty-day effects of initial composite interventions for the treatment of
severely and critically ill patients with COVID-19 are not fully assessed. Methods: Using a …

Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …

Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19
in China due to their earlier approval by the National Medical Products Administration …

We report here the synthesis and biological evaluation of a series of small molecule SARS-
CoV-2 PLpro inhibitors. We compared the activity of selected compounds in both SARS-CoV …

Objective To assess the effectiveness of nirmatrelvir-ritonavir in the treatment of outpatients
with mild to moderate COVID-19 who are at higher risk of developing severe illness, through …

In this retrospective comparative study, we evaluated the effectiveness of remdesivir (RDSV)
in patients with SARS-CoV-2 pneumonia. Individuals hospitalized between March 2020 and …

BACKGROUND Patients hospitalized for COVID-19 exhibit diverse clinical outcomes, with
outcomes for some individuals diverging over time even though their initial disease severity …